ST柳化(600423.SH)2020年實現扭虧 預盈1200萬元
格隆匯1月26日丨ST柳化(600423.SH)披露2020年度業績預盈公吿,公司預計2020年度實現歸屬於上市公司股東的淨利潤與上年同期(法定披露數據)相比,將實現扭虧為盈,實現歸屬於上市公司股東的淨利潤1200萬元;扣除非經常性損益後,歸屬於上市公司股東的淨利潤980萬元。
業績預盈主要原因系:一方面,報吿期內,公司進一步加強了生產經營和工藝技術管理,生產系統實現穩產高產,27.5%雙氧水年累計產量突破了10萬噸/年的設計能力,同時下半年,特別是進入四季度以後,受供求關係影響,產品價格上漲,銷售收入和利潤增加;另一方面,報吿期內,公司加強了貨幣資金管理,銀行利息收入增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.